| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 81408 |
|
5,919 |
4,855 |
$5.74M |
| 81406 |
|
7,467 |
6,061 |
$5.31M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
51,940 |
16,544 |
$5.14M |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
6,900 |
5,977 |
$3.86M |
| 81162 |
|
2,328 |
2,058 |
$2.60M |
| 81405 |
|
7,418 |
6,230 |
$2.15M |
| 81255 |
|
5,214 |
4,571 |
$1.38M |
| 81211 |
|
715 |
636 |
$1.26M |
| 81404 |
|
6,765 |
5,641 |
$1.24M |
| 81407 |
|
3,340 |
2,815 |
$891K |
| 81321 |
|
2,745 |
2,447 |
$772K |
| 81298 |
|
2,549 |
2,252 |
$721K |
| 81317 |
|
2,497 |
2,195 |
$650K |
| 81292 |
|
2,473 |
2,184 |
$640K |
| 81200 |
|
4,221 |
3,626 |
$597K |
| 81201 |
|
2,269 |
1,987 |
$594K |
| 81251 |
|
3,979 |
3,495 |
$591K |
| 81209 |
|
4,298 |
3,695 |
$588K |
| 81290 |
|
4,279 |
3,679 |
$584K |
| 81260 |
|
4,054 |
3,563 |
$583K |
| 81295 |
|
2,563 |
2,271 |
$534K |
| 81242 |
|
4,206 |
3,618 |
$390K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
28,542 |
8,403 |
$372K |
| 81364 |
|
2,951 |
2,542 |
$335K |
| 81307 |
|
1,562 |
1,397 |
$286K |
| 81213 |
|
607 |
560 |
$280K |
| 81329 |
|
4,260 |
3,631 |
$269K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,770 |
1,706 |
$251K |
| 81257 |
|
4,235 |
3,633 |
$249K |
| 81403 |
|
2,661 |
2,190 |
$161K |
| 81243 |
|
1,676 |
1,506 |
$152K |
| 81252 |
|
3,465 |
2,919 |
$139K |
| 81205 |
|
2,700 |
2,336 |
$85K |
| 81226 |
|
625 |
595 |
$68K |
| 81401 |
|
545 |
409 |
$52K |
| 81254 |
|
3,365 |
2,887 |
$48K |
| 81225 |
|
725 |
682 |
$43K |
| 81323 |
|
1,433 |
1,283 |
$41K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,340 |
1,042 |
$40K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,343 |
949 |
$37K |
| 81336 |
|
204 |
140 |
$24K |
| 81418 |
|
332 |
315 |
$19K |
| 81479 |
Unlisted molecular pathology procedure |
1,535 |
1,356 |
$15K |
| 81300 |
|
1,370 |
1,225 |
$11K |
| 81297 |
|
1,373 |
1,226 |
$11K |
| 81328 |
|
386 |
347 |
$10K |
| 81294 |
|
1,372 |
1,225 |
$10K |
| 81203 |
|
965 |
871 |
$9K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
80 |
42 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
360 |
168 |
$3K |
| 81227 |
|
18 |
16 |
$874.53 |
| 87631 |
|
16 |
16 |
$533.75 |
| 87486 |
|
13 |
13 |
$210.54 |
| 87581 |
|
13 |
13 |
$210.54 |
| 81319 |
|
591 |
546 |
$0.00 |
| 81443 |
|
48 |
35 |
$0.00 |